Entheon Biomedical Inc. is a biotechnology company committed to the development of safe and effective psychedelic medicines in order to provide patients with access to evidence-based treatments for addiction disorders.
The company is researching patented psilocybin-based and DMT-based formulations for products for the treatment of addiction disorders. Beginning with animal toxicology and behavioral studies, the company plans to follow the strict regulatory pathways of classic drug discovery and approval before moving into human clinical trials and commercialization.
Chief Executive Officer
Chief Financial Officer
Andrew Hegle, Ph.D.
Director or Operations
Christopher Gondi, Ph.D., M.Sc.
Chief Scientific Officer